JP2020522529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522529A5 JP2020522529A5 JP2019567258A JP2019567258A JP2020522529A5 JP 2020522529 A5 JP2020522529 A5 JP 2020522529A5 JP 2019567258 A JP2019567258 A JP 2019567258A JP 2019567258 A JP2019567258 A JP 2019567258A JP 2020522529 A5 JP2020522529 A5 JP 2020522529A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- icm
- rankl
- rank
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940126546 immune checkpoint molecule Drugs 0.000 claims 2
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102000014128 RANK Ligand Human genes 0.000 claims 1
- 108010025832 RANK Ligand Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017902125 | 2017-06-05 | ||
| AU2017902125A AU2017902125A0 (en) | 2017-06-05 | "Agents for cancer therapy or prophylaxis and uses therefor" | |
| PCT/AU2018/050557 WO2018223182A1 (en) | 2017-06-05 | 2018-06-05 | A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522529A JP2020522529A (ja) | 2020-07-30 |
| JP2020522529A5 true JP2020522529A5 (enExample) | 2021-07-26 |
Family
ID=64565634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567258A Pending JP2020522529A (ja) | 2017-06-05 | 2018-06-05 | 癌の治療または予防のための薬剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230042913A1 (enExample) |
| EP (1) | EP3634484A4 (enExample) |
| JP (1) | JP2020522529A (enExample) |
| CN (1) | CN111032085A (enExample) |
| AU (1) | AU2018280340A1 (enExample) |
| CA (1) | CA3065836A1 (enExample) |
| WO (1) | WO2018223182A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| JP2022514215A (ja) * | 2018-12-05 | 2022-02-10 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | Ｒａｎｋアンタゴニストおよびその使用 |
| KR20220008253A (ko) * | 2019-01-03 | 2022-01-20 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) | 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물 |
| CN110179977A (zh) * | 2019-05-22 | 2019-08-30 | 华中科技大学同济医学院附属同济医院 | 用于治疗黑色素瘤、肺癌或结直肠癌的组合药物制剂 |
| WO2020252329A1 (en) * | 2019-06-14 | 2020-12-17 | The Scripps Research Institute | Immune checkpoint blocking bispecific molecules |
| US20220267467A1 (en) * | 2019-07-19 | 2022-08-25 | WuXi Biologics Ireland Limited | Polypeptide complex for conjugation and use thereof |
| CN110938652A (zh) * | 2019-11-07 | 2020-03-31 | 浙江大学医学院附属第一医院 | 打靶载体及构建白喉毒素调控清除巨噬细胞的f4/80-dtr转基因小鼠的方法和应用 |
| WO2021115465A1 (en) * | 2019-12-13 | 2021-06-17 | Biosion Inc. | Antibodies binding rankl and uses thereof |
| MX2022007840A (es) * | 2019-12-27 | 2022-07-19 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla4) y uso del mismo. |
| SE544001C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody |
| SE544000C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein |
| CN111808198B (zh) * | 2020-07-27 | 2022-06-03 | 广东安普泽生物医药股份有限公司 | 一种特异性结合rankl靶向治疗药物的抗体及其应用 |
| TW202305009A (zh) * | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
| TWI833242B (zh) * | 2021-06-11 | 2024-02-21 | 大陸商廣東菲鵬製藥股份有限公司 | 抗pd-1人源化抗體或其抗原結合片段、編碼其的核酸、包含其的載體、細胞和藥物組合物及其用途 |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| WO2023010098A2 (en) * | 2021-07-28 | 2023-02-02 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel multi-specific molecules |
| CN113929785B (zh) * | 2021-09-10 | 2023-05-23 | 钦元再生医学(珠海)有限公司 | 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用 |
| WO2024104409A1 (zh) * | 2022-11-16 | 2024-05-23 | 苏州盛迪亚生物医药有限公司 | 一种含抗rankl-ngf双特异性抗体的药物组合物 |
| WO2024126750A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Methods for treating cancer |
| TW202434643A (zh) | 2023-01-09 | 2024-09-01 | 大陸商北京拓界生物醫藥科技有限公司 | ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途 |
| TW202525857A (zh) * | 2023-09-11 | 2025-07-01 | 大陸商上海才致藥成生物科技有限公司 | 長效副甲狀腺激素受體促效劑融合蛋白及其應用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8242247B2 (en) * | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2011017294A1 (en) * | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
| MX2016008667A (es) * | 2013-12-30 | 2017-02-02 | Epimab Biotherapeutics Inc | Inmunoglobulina con fab en tandem y usos de esta. |
| CN104861067A (zh) * | 2014-01-10 | 2015-08-26 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
| US20150307620A1 (en) * | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| MX2018009581A (es) * | 2016-02-06 | 2019-05-06 | Epimab Biotherapeutics Inc | Inmunoglobulina con fabs en tandem y sus usos. |
| DE202017007721U1 (de) * | 2016-05-20 | 2025-02-11 | Christoph Karl | Pharmazeutische Zusammensetzungen mit Anti-RANKL-Antikörpern, Kalzium und Vitamin D, geeignet zur Behandlung und/oder Prophylaxe von Erkrankungen des Knochenstoffwechsels und von therapiebedingten Nebenwirkungen wie Hypokalzämien |
| CA3034453A1 (en) * | 2016-08-25 | 2018-03-01 | AI Therapeutics, Inc. | Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling |
-
2018
- 2018-06-05 JP JP2019567258A patent/JP2020522529A/ja active Pending
- 2018-06-05 US US16/619,891 patent/US20230042913A1/en not_active Abandoned
- 2018-06-05 CN CN201880050953.5A patent/CN111032085A/zh active Pending
- 2018-06-05 AU AU2018280340A patent/AU2018280340A1/en not_active Abandoned
- 2018-06-05 EP EP18813354.0A patent/EP3634484A4/en not_active Withdrawn
- 2018-06-05 CA CA3065836A patent/CA3065836A1/en active Pending
- 2018-06-05 WO PCT/AU2018/050557 patent/WO2018223182A1/en not_active Ceased